Literature DB >> 24549717

Generation of infectious HCV pseudo typed particles and its utilization for studying the role of CD81 & SRBI receptors in HCV infection.

Shazia Rafique1, Muhammad Idrees, Amjad Ali, Kashif Iqbal Sahibzada, Muhammad Iqbal.   

Abstract

Hepatitis C virus (HCV) entry into isolated primary liver cells and cell lines requires interaction with the cell surface receptors. The study of HCV attachment with host cell surface receptors has been hindered by the unavailability of competent cell culture based system for HCV propagation. This problem has been overcome by the development of genetically tagged infectious HCV pseudo particles (HCVpp) harboring unmodified E1 and E2 glycoproteins. Studies using cell binding assays together with infection assays using HCVpp have shown that CD81 and scavenger receptor (SRBI) are actively involved in binding with envelope proteins facilitating the viral entrance process. This paper aimed to develop HCVpp of local HCV 3a Pakistani isolate and to study the viral tropism role of CD81 and SRBI receptors in HCV infectivity. HCV E1 and E2 genes were amplified and cloned in mammalian expression vector pcDNA 3.1/myc. The expressing plasmid of HCV E1-E2 glycoprotein in native form was co-transfected into 293FT cells with lentiviral packaging plasmid encoding the MLV Gag-Pol core proteins, and a packaging competent MLV-derived genome (pMLVYCMV-Luc) encoding the luciferase marker protein to produce infectious HCVpp. Anti-CD81 antibody (CBL579), anti-SRBI type II antibody (sc-20441) HCV anti-E2 mouse IgG1 (sc-65457) and HCV anti-E1 antibody mouse IgG1 (sc-65459) were used in this setup. We showed that primary site of viral replication is liver which involve CD81 and SRBI receptors for HCV gp-dependent infection with HCVpp. This is the preliminary reported cell cultured based mechanism from Pakistan which facilitated functional studies of different antiviral agents. Understanding of this technique will help in development of new antiviral therapeutics focusing on earlier steps of HCV life cycle. We have developed infectious pseudo particles of local 3a-isolate and concluded that a number of liver-specific surface proteins function along with CD81 and SRBI receptor regarding HCV infectivity. To endeavors and to identify this liver specific co-receptor molecule(s) will provide insights into the role of these molecules in the initial steps of HCV life cycle.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24549717     DOI: 10.1007/s11033-014-3247-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  44 in total

Review 1.  Peginterferon and ribavirin for chronic hepatitis C.

Authors:  Jay H Hoofnagle; Leonard B Seeff
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

2.  Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp).

Authors:  Annemarie Berger; Tsanan Giroglou; Anke Leutz; Henry Ogbomo; Kerstin Pfaff; Gerlinde Teuber; Jindrich Cinatl; Dorothee van Laer; Hans Wilhelm Doerr
Journal:  J Clin Virol       Date:  2009-06-26       Impact factor: 3.168

3.  Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2.

Authors:  A Higginbottom; E R Quinn; C C Kuo; M Flint; L H Wilson; E Bianchi; A Nicosia; P N Monk; J A McKeating; S Levy
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I.

Authors:  Cécile Voisset; Nathalie Callens; Emmanuelle Blanchard; Anne Op De Beeck; Jean Dubuisson; Ngoc Vu-Dac
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

5.  Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.

Authors:  Arvind H Patel; Jonny Wood; Francois Penin; Jean Dubuisson; J A McKeating
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

6.  Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins.

Authors:  Linda Buonocore; Keril J Blight; Charles M Rice; John K Rose
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.

Authors:  Mayla Hsu; Jie Zhang; Mike Flint; Carine Logvinoff; Cecilia Cheng-Mayer; Charles M Rice; Jane A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-21       Impact factor: 11.205

8.  Characterization of functional hepatitis C virus envelope glycoproteins.

Authors:  Anne Op De Beeck; Cécile Voisset; Birke Bartosch; Yann Ciczora; Laurence Cocquerel; Zhenyong Keck; Steven Foung; François-Loïc Cosset; Jean Dubuisson
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent.

Authors:  Sonia Molina; Valerie Castet; Lydiane Pichard-Garcia; Czeslaw Wychowski; Eliane Meurs; Jean-Marc Pascussi; Camille Sureau; Jean-Michel Fabre; Antonio Sacunha; Dominique Larrey; Jean Dubuisson; Joliette Coste; Jane McKeating; Patrick Maurel; Chantal Fournier-Wirth
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

10.  Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.

Authors:  Joe Grove; Søren Nielsen; Jin Zhong; Margaret F Bassendine; Heidi E Drummer; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

View more
  1 in total

1.  The function of SARS-CoV-2 spike protein is impaired by disulfide-bond disruption with mutation at cysteine-488 and by thiol-reactive N-acetyl-cysteine and glutathione.

Authors:  Mana Murae; Yoshimi Shimizu; Yuichiro Yamamoto; Asuka Kobayashi; Masumi Houri; Tetsuya Inoue; Takuya Irie; Ryutaro Gemba; Yosuke Kondo; Yoshio Nakano; Satoru Miyazaki; Daisuke Yamada; Akiyoshi Saitoh; Isao Ishii; Taishi Onodera; Yoshimasa Takahashi; Takaji Wakita; Masayoshi Fukasawa; Kohji Noguchi
Journal:  Biochem Biophys Res Commun       Date:  2022-01-29       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.